BioSpace News Archive

Varex Imaging Corporation announced its unaudited financial results for the second quarter of fiscal year 2020.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, announced its financial results for the first quarter 2020 and provided a corporate update.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will present a corporate overview at the following conferences being held virtually

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, reported financial results from the first quarter ending March 31, 2020 and provided an update on corporate activities.

Danaher Corporation announced that it has closed concurrent offerings of 9,509,203 shares of common stock at a price to the public of $163.00 per share and 1,717,500 shares of 5.00% Series B Mandatory Convertible Preferred Stock at a price to the public of $1,000 per share.

Top-Line Results Expected in Q4 2020 from Fully Enrolled Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy

Bruker Corporation announced it will present at the following virtual conferences

Jefferson Radiology, an affiliate of MEDNAX and Center for Diagnostic Imaging announced the launch of a new collaborative agreement for CDI’s Springfield location, combining physician excellence with industry leading technological capabilities to further cement their reputations as providers of choice in the Springfield market.

Novel dual-balloon technology designed for true 360° stent apposition [12-May-2020] CAMPBELL, Calif. , May 12, 2020 /PRNewswire/ -- Ostial Corporation (Ostial), a private medical technology company focused on addressing the clinical challenges of aorto-ostial interventions, today reached a new milestone, passing the mark of 15,000 commercial units sold of its FLASH™

Insulet Corporation, a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced that it plans to make an offering of $500 million of its common stock in a registered underwritten offering.